▲ 2.10%
prev close
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Congressional Trades
3
All tracked trades
Members Trading
1
Unique members
Net Activity
+3
3 buys · 0 sells
Members Who Traded This Stock
3 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-01-16 | GMABGenmab A/S - American Depositary Shares | Buy | $1,001 - $15,000 | 527d ago | — | |
| 2024-07-19 | GMABGenmab A/S - American Depositary Shares | Buy | $1,001 - $15,000 | 706d ago | — | |
| 2023-07-20 | GMABGenmab A/S - American Depositary Shares | Buy | $1,001 - $15,000 | 1066d ago | — |
2025-01-16
Josh Gottheimer
GMAB
Amount
$1,001 - $15,000
Filed
527d ago
2024-07-19
Josh Gottheimer
GMAB
Amount
$1,001 - $15,000
Filed
706d ago
2023-07-20
Josh Gottheimer
GMAB
Amount
$1,001 - $15,000
Filed
1066d ago
Recent News
Powered by Polygon.io
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Trade Timeline
Congressional activity, newest first
Josh Gottheimer
2025-01-16 · Purchase
$1,001 - $15,000
Josh Gottheimer
2024-07-19 · Purchase
$1,001 - $15,000
Josh Gottheimer
2023-07-20 · Purchase
$1,001 - $15,000